The interest in antibodies, both as tools generating new knowledge or as medical interventions to address health concerns, continues to grow. Since the Phage Display System is a well-established technology, the Indiana Biosciences Research Institute (IBRI) entered into a licensing agreement with Eli Lilly and Company to gain access to its proprietary human Fab Phage Display Library platform.
This platform is a combination of multiple libraries of known bacteriophages that contains the genetic information that encodes them. It also provides both molecular diversity and high throughput capacity allowing the selection of antibodies with high affinity and specificity for almost any target.
In addition to its internal efforts, the IBRI will establish partnerships to utilize the library for developing new diagnostic tools and therapeutic interventions for a range of disease targets. Through the licensing of its library, Lilly is hopeful that the IBRI and its partners can make meaningful therapeutic advancements that lead to improved health for patients.
Back to Scientific Resources.
- Indiana University School of Medicine